wellrank.ai
Skyrizi logo

Skyrizi

First cited by AI Jun 12, 2026

Surfaced organically in AI answers about online dermatology. Not yet profiled.

Skyrizi is losing the AEO war.

Not cited in a single tracked AI answer since Jun 12, 2026, down from a peak of 8% visibility in online dermatology on Jun 12, 2026. This page and its history stay public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

Online dermatology, daily share of AI answers mentioning Skyrizi, through Jun 13, 2026.

0.0%

Last cited Jun 12, 2026 · peak 8% on Jun 12

By engine

Where Skyrizi is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 1 neutral
  • 0 mixed or cautious

Recent AI answers mentioning Skyrizi

Google AIJun 12, 2026, 11:06 UTC
How much does online dermatology cost compared to a dermatologist visit?

The cost of online dermatology can vary, but it's generally less expensive than an in-person visit to a traditional dermatologist. Here's a breakdown of what you can expect: Online Dermatology Costs: Per-Visit Fees: Most online dermatology services operate on a pay-per-visit model. You'll typically pay a flat fee for a consultation, which can range from $30 to $150. Some services offer subscription models that provide a certain number of consultations per year for a set price. Treatment Costs: The cost of prescriptions or recommended treatments is separate from the consultation fee. This will depend on the medication or product prescribed and your insurance coverage. Brands/Services to Consider for Online Dermatology: Apostrophe: Known for its competitive pricing, often around $75 per consultation. They have a user-friendly platform and connect you with board-certified dermatologists. Skyrizi: While Skyrizi is a medication for specific conditions like psoriasis, they do offer support programs and resources that can indirectly help with cost management and access to care, sometimes through telehealth options. It's worth checking their website for patient assistance programs. Nurx: Offers a range of services, including acne treatment, birth control, and more. Their consultations can be around $30-$40 for the initial assessment, plus the cost of medication. They are often praised for their accessibility and affordability. Hims/Hers: These platforms offer a variety of health services, including dermatology for men (Hims) and women (Hers). Consultations can range from $39-$60 for the initial visit, with ongoing treatment plans available. They are convenient for common skin concerns. Traditional Dermatologist Visit Costs: Co-pays: If you have health insurance, your co-pay for a specialist visit can range from $25 to $100+, depending on your plan. Out-of-Pocket Costs: Without insurance, a single dermatology visit can cost anywhere from $100 to $300+, not including any diagnostic tests, procedures, or prescriptions. Additional Costs: You might incur extra costs for biopsies, skin scrapings, cryotherapy, or other in-office procedures. Why Online Dermatology is Often Cheaper: Lower Overhead: Online dermatology practices have significantly lower overhead costs compared to brick-and-mortar clinics (rent, staff, equipment). Streamlined Processes: The consultation process is often more efficient, with patients submitting photos and details online. Focus on Common Conditions: Many online services are geared towards diagnosing and treating common dermatological issues like acne, rashes, and mild infections, which may not require extensive in-person examination. When to Consider a Traditional Dermatologist: While online dermatology is convenient and cost-effective for many concerns, it's important to remember that it's not a replacement for all in-person care. You should see a traditional dermatologist if you have: A suspicious mole that could be skin cancer. A rapidly changing or unusual skin lesion. A severe or persistent skin condition that isn't improving with over-the-counter treatments. A condition that requires a physical examination or in-office procedure. In summary: For many common skin concerns, online dermatology is a more affordable and accessible option than visiting a traditional dermatologist in person. However, always prioritize your health and seek in-person care when necessary.

Mentioned in position 2 of 4

Read full answer with sources →

Public AI visibility history

Daily rank of Skyrizi on our buyer intent questions, per category. A dash means the engines did not cite Skyrizi at all that day. This record is permanent.

CategoryJun 11Jun 12Jun 13
Online dermatology#31

TL;DR

Skyrizi (risankizumab) is a prescription biologic medication developed and marketed by AbbVie, approved to treat moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is not a telehealth platform itself but surfaces in AI-generated answers within the online dermatology category, where WellRank currently places it at #15 with 8% AI visibility, reflecting its organic appearance in discussions about treatments patients may seek through digital dermatology services.

Company Overview

Skyrizi is a branded biologic therapy owned and commercialized by AbbVie, a publicly traded global biopharmaceutical company headquartered in North Chicago, Illinois. AbbVie markets Skyrizi directly to healthcare providers and patients, relying on a prescription-only, physician-dispensed model. The product does not operate as a standalone company but functions as one of AbbVie's major immunology franchises.

Product Features

  • Risankizumab, a selective IL-23 inhibitor administered by injection
  • Approved indication for moderate-to-severe plaque psoriasis in adults
  • Approved indication for active psoriatic arthritis
  • Approved indication for moderately to severely active Crohn's disease
  • Approved indication for moderately to severely active ulcerative colitis
  • Administered via subcutaneous injection or intravenous induction depending on indication

Target Market

Skyrizi is prescribed to adults living with moderate-to-severe immune-mediated inflammatory conditions including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. It is available in the United States, the European Union, and numerous other markets globally. Patients typically access it through dermatologists, gastroenterologists, or rheumatologists rather than directly through consumer telehealth channels.

Buyer Personas

  • An adult with moderate-to-severe plaque psoriasis who has not responded adequately to topical or conventional systemic therapies and is seeking a biologic option.
  • A patient with psoriatic arthritis managing both joint and skin symptoms who needs a treatment addressing both disease aspects.
  • An adult with Crohn's disease or ulcerative colitis whose condition is not controlled by conventional therapies and whose gastroenterologist recommends a biologic escalation.
  • A health-conscious consumer researching dermatology treatments online who encounters Skyrizi in AI-generated answers or telehealth platform discussions.

Funding & Performance

Skyrizi is a product line of AbbVie, a publicly traded company listed on the New York Stock Exchange under the ticker ABBV. Skyrizi-specific revenue figures are reported periodically in AbbVie's public earnings disclosures, where it has been cited as one of the company's fastest-growing franchises, though segment-level breakdowns vary by reporting period.

Recent Developments

AbbVie has expanded Skyrizi's approved indications beyond plaque psoriasis to include inflammatory bowel disease conditions, broadening its addressable patient population considerably. The company has also invested in patient support programs and has pursued label expansions in multiple geographies, reinforcing Skyrizi's position as a central pillar of AbbVie's post-Humira immunology portfolio.

Competitive Landscape

Within the online dermatology AI-answer space tracked by WellRank, Skyrizi is co-mentioned most frequently alongside Nurx, Hims & Hers, and Apostrophe, which are consumer telehealth platforms rather than direct biologic competitors. Its true therapeutic competitors are other IL-23 and IL-17 inhibitor biologics such as Tremfya, Taltz, and Cosentyx, which compete for the same prescriber and patient populations across dermatology and rheumatology.

Skyrizi vs the brands AI recommends alongside it

The real competitive set in Online dermatology: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Skyrizi logo
SkyriziThis brand
0.0%
Apostrophe logo
Apostrophe

1 shared answers

#2
50.0%
Hims & Hers logo
Hims & Hers

1 shared answers

#12
8.3%
Nurx logo
Nurx

1 shared answers

#3
50.0%

Email me when overtakes Skyrizi

One email the day the ranks flip. Nothing else.

User Sentiment

Based on WellRank's current corpus, Skyrizi has appeared in one AI-generated mention in the online dermatology category, and that mention carries a neutral tone with no positive or cautionary framing recorded. This suggests AI engines reference Skyrizi as a factual treatment option rather than offering evaluative commentary, which is consistent with how clinical therapeutics are generally handled in AI health answers.

Pricing

Skyrizi is a specialty biologic and its list price is not a stable, widely cited public figure in the way consumer product pricing is. Actual patient out-of-pocket costs vary significantly depending on insurance coverage, manufacturer co-pay assistance programs, and pharmacy benefit design, so pricing is not published in simple consumer terms.

Sources cited around Skyrizi

The sites engines cite in answers mentioning this brand. Win these, win the answer.

    Track Skyrizi weekly

    One email a week: rank moves, new competitors, and the answers that changed. No noise.

    Work at Skyrizi? Get your AI Visibility Audit.

    See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.

    Skyrizi: AI visibility report | WellRank